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Abstract 
Background: Q fever fatigue syndrome (QFS) is a well‑documented state of prolonged fatigue following around 20% 
of acute Q fever infections. It has been hypothesized that low grade inflammation plays a role in its aetiology. In this 
study, we aimed to identify transcriptome profiles that could aid to better understand the pathophysiology of QFS.
Methods: RNA of monocytes was collected from QFS patients (n = 10), chronic fatigue syndrome patients (CFS, 
n = 10), Q fever seropositive controls (n = 10), and healthy controls (n = 10) who were age‑ (± 5 years) and sex‑
matched. Transcriptome analysis was performed using RNA sequencing.
Results: Mitochondrial‑derived peptide (MDP)‑coding genes MT‑RNR2 (humanin) and MT‑RNR1 (MOTS‑c) were 
differentially expressed when comparing QFS (− 4.8 log2‑fold‑change P = 2.19 × 10−9 and − 4.9 log2‑fold‑change 
P = 4.69 × 10−8), CFS (− 5.2 log2‑fold‑change, P = 3.49 × 10−11 − 4.4 log2‑fold‑change, P = 2.71 × 10−9), and Q fever 
seropositive control (− 3.7 log2‑fold‑change P = 1.78 × 10−6 and − 3.2 log2‑fold‑change P = 1.12 × 10−5) groups 
with healthy controls, resulting in a decreased median production of humanin in QFS patients (371 pg/mL; Interquar‑
tile range, IQR, 325–384), CFS patients (364 pg/mL; IQR 316–387), and asymptomatic Q fever seropositive controls 
(354 pg/mL; 292–393).
Conclusions: Expression of MDP‑coding genes MT‑RNR1 (MOTS‑c) and MT‑RNR2 (humanin) is decreased in CFS, QFS, 
and, to a lesser extent, in Q fever seropositive controls, resulting in a decreased production of humanin. These novel 
peptides might indeed be important in the pathophysiology of both QFS and CFS.
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Background
Q fever is a zoonotic disease caused by the intracellular 
Gram-negative bacterium Coxiella burnetii. Humans 
usually become infected through inhalation of infected 
aerosols that arise from small ruminants, of which par-
turient fluids are most notorious [1]. The bacterium pri-
marily infects alveolar macrophages [1, 2]. By subverting 
host cell functions such as Toll-like receptor (TLR) rec-
ognition, apoptosis, and vesicular trafficking, C. burnetii 
is able to survive and replicate inside the phagolysosome 
of monocytes and macrophages [2]. Once inside the 
phagolysosome, the Coxiella Containing Vacuole (CCV), 
C. burnetii employs a Dot/Icm type IV secretion system 
through which it manipulates host cell processes [3, 4]. It 
is assumed that immune competent individuals are able 
to clear the infection eventually, making Q fever a self-
limiting disease.
Initial infection with C. burnetii leads to symptomatic 
disease, i.e., acute Q fever, in around 40% of cases. This 
often presents as a flu-like illness, which is sometimes 
accompanied by pneumonia or hepatitis [2]. Of all those 
who become infected, around 1–5% develop a persistent 
infection with C. burnetii, chronic Q fever or persistent 
focalised infection, usually manifesting as endocarditis 
or infection of pre-existing aneurysms or vascular pros-
theses [1, 5]. Q fever fatigue syndrome (QFS) occurs in 
around 20% of symptomatic acute Q fever infections. 
QFS is characterised by a state of prolonged fatigue that 
lasts at least 6  months and often coincides with several 
other complaints, leading to substantial disabilities [6].
Complaints such as fatigue, musculoskeletal pain, 
headache, night sweating and recurrent upper respiratory 
tract infections suggest an inflammatory component in 
QFS. Active infection has however not been convincingly 
shown in these patients. In accordance with this, the first 
randomized placebo-controlled trial for QFS treatment 
was recently published, comparing cognitive behavioural 
therapy (CBT) and doxycycline with placebo treatment, 
demonstrating a beneficial effect for CBT, but not doxy-
cycline, in reducing fatigue severity at end of treatment 
[7]. In 1998, Pentilla et al. published that peripheral blood 
mononuclear cells (PBMCs) of QFS patients produce sig-
nificantly more interleukin (IL)-6 than cells of various 
control groups when exposed to Q fever antigens [8]. Our 
group has demonstrated that QFS patients show signs of 
altered immunity through monocyte-derived cytokines 
tumor necrosis factor (TNF)α, IL-1β, and especially IL-6, 
together with the interferon (IFN)γ- axis [9–11].
Chronic fatigue syndrome (CFS) is a disease with a 
striking overlap in symptoms with QFS that shows a 
subtle difference in psychological perpetuating factors 
and inflammatory profile [11, 12]. As in QFS, the aetiol-
ogy of CFS remains unclear and is thought to involve the 
immune system [11, 13, 14], possibly through, or in com-
bination with, mitochondrial dysfunction [15–17]. Com-
plaints such as fatigue and exercise intolerance in CFS, 
but also QFS, strengthen the theory that mitochondrial 
dysfunction is involved in its pathogenesis.
To further elucidate the pathophysiology of chronic 
fatigue syndromes such as QFS and CFS, we used next-
generation sequencing to investigated the transcriptomes 
of unstimulated circulating monocytes of QFS patients, 
CFS patients, asymptomatic Q fever seropositive con-
trols, and healthy controls, all matched for age and sex.
Methods
Study population
The study population consisted of QFS patients (n = 10), 
CFS patients (n = 11), asymptomatic Q fever seropositive 
controls (n = 10), and healthy controls (n = 10), matched 
for age (± 5 years) and sex.
All QFS patients were diagnosed at the Radboud 
Expert Center for Q fever, Nijmegen, the Netherlands, 
after a uniform work-up according to the Dutch guideline 
on QFS [18]. All QFS patients met the following diagnos-
tic criteria: (i) fatigue lasted ≥ 6 months; (ii) sudden onset 
of severe fatigue (defined as a score ≥ 35 on the subscale 
fatigue severity of the Checklist Individual Strength (CIS) 
questionnaire) [19] (Additional file 1: Table S1), or signif-
icant increase in fatigue, both related to a symptomatic 
acute Q fever infection; iii. chronic Q fever and other 
somatic or psychiatric causes of fatigue were excluded; 
and iv. fatigue resulted in significant functional impair-
ment (defined as a total score ≥ 450 on the Sickness 
Impact Profile-8 (SIP-8) questionnaire) [20] (Additional 
file 1: Table S2).
All CFS patients were diagnosed at the Department 
of Internal Medicine and Expert Center for Chronic 
Fatigue (ECCF) of the Radboud university medical 
center, Nijmegen, the Netherlands, after a uniform work-
up according to the Centers for Disease Control (CDC) 
criteria for CFS [21], strengthened with scores on SIP-8 
and CIS, subscale on fatigue severity, questionnaires. All 
CFS patients tested negative on Q fever serology (Immu-
nofluorescence assay, or IFA; Focus Diagnostics, Cypress, 
CA, USA) and, additionally, had a score ≥ 35 on the 
subscale fatigue severity of the CIS questionnaire and a 
score ≥ 450 on the SIP-8 questionnaire.
Asymptomatic Q fever seropositive controls were 
asked to participate by the primary investigator (RR); 
all of them tested positive on Q fever serology ≥ 5 years 
after the Q fever outbreak that took place between 2007 
and 2011 (IgG phase I or II ≥ 1:16, but IgG phase I < 512), 
and reported no complaints of fatigue or functional 
impairment.
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Colleagues from the Department of Internal Medicine 
at the Radboud university medical center, Nijmegen, who 
lived in areas previously endemic for Q fever during the 
Dutch outbreak between 2007 and 2011, tested negative 
on Q fever serology (IFA), and reported no complaints of 
fatigue or functional impairment, were asked to partici-
pate by the primary investigator (RR) as healthy controls.
PBMC and monocyte isolation
PBMC were isolated by dilution of blood in PBS (1:1) and 
fractions were separated by density centrifugation over 
Ficoll-Paque (Ficoll-Paque Plus; GE healthcare, Zeist, The 
Netherlands). Cells were washed three times with cold 
PBS and resuspended in RPMI 1640 Dutch modification 
culture medium (Life Technologies/Invitrogen, Breda, 
The Netherlands) supplemented with 50  μg/mL gen-
tamicin, 2 mM Glutamax, and 1 mM pyruvate (Life Tech-
nologies). Percoll isolation of monocytes was performed 
as previously described [22]. Briefly, 150–200  ×  106 
PBMCs were layered on top of a hyper-osmotic Percoll 
solution (48.5% Percoll, 41.5% sterile  H2O, 0.16  M fil-
ter sterilized NaCl) and centrifuged for 15  min at 580g. 
The interphase layer was isolated and cells were washed 
once with cold PBS. Cells were resuspended in culture 
medium as described above.
PBMC stimulation and peptide assays
PBMCs were plated in 96-well round-bottom plates 
(Corning) at a concentration of 5 × 105/mL in a total vol-
ume of 200 µL. The samples were stimulated with 10 ng/
mL lipopolysaccharide (LPS) (Sigma-Aldrich, St. Louis, 
MO; from E. coli) for 24 h at 37  °C with 5%  CO2. After 
stimulation, supernatants were collected and stored at 
−  20  °C until peptide assays were performed. Huma-
nin and MOTS-c were measured using enzyme-linked 
immune sorbent assay (ELISA) according to the manu-
facturer protocol (MyBioSource, San Diego, CA, USA).
RNA isolation and quantification
RNA was isolated from the monocyte-enriched sus-
pension using the mirVana™ miRNA Isolation Kit 
(Ambion, Austin, TX, USA) according to the manufac-
turer’s instructions. The purity and quantity of RNA were 
assessed using NanoDrop software, after which samples 
were immediately stored at − 80 °C for future use.
RNA sequencing alignment and expression analysis
RNA sequencing was performed on monocytes from 
all patients and transcriptome data is available at Gene 
Expression Omnibus (GSE130353) [23]. Reads were 
aligned using GSNAP [24], using non-default param-
eters −m 1 −N 1 −n 1 −Q −s Ensembl_splice_68. 
RNA sequencing library data were initially subjected to 
a quality control step, where, based on read distribution 
over the annotated genome, libraries that are outliers 
were identified and discarded from further analysis. For 
expression analyses reads were aligned to the Ensembl 
v68 human transcriptome using Bowtie. Quantification 
of gene expression was performed using MMSEQ.
Differential expression
Analysis was performed using DESeq2, using as input 
the MMSEQ counts (Unique hits). Only genes with aver-
age counts above 1 were fed into the DESeq2 software. 
DESeq2 internally performs another round of independ-
ent filtering (usually the filter threshold of average num-
ber of reads would be ~ 5). To check for the main source 
of variation, principal component analysis (PCA) was 
performed on the top 500 varying genes (Additional 
file 1: Table S3).
Pathway enrichment analysis
For the analysis of over- and underrepresented biologi-
cal pathways, comparing the various groups (n = 10), 
the ClueGo V2.1.7 appliance was used in the integrative 
bio-informatic software environment of Cytoscape V3.2. 
Pathways were significantly overexpressed if they showed 
a P value ≤ 0.05 and only differentially expressed genes 
with a P value < 0.01 were selected for pathway analysis. 
Various analysis pathways like Kyoto Encyclopedia of 
Genes and Genomes pathway (KEGG), Reactome path-
way, and Wikipathway were used on the differentially 
expressed gene lists, followed by Benjamini–Hochberg 
adjustment for terms and groups.
Statistical analysis
Patient characteristics data were analyzed using Graph-
pad Prism (Graphpad Software Inc., version 5.03) and 
SPSS (Version 22.0, SPSS, Inc). The Mann–Whitney and 
Kruskal–Wallis test were used as non-parametric t-test 
and ANOVA to determine differences between groups. 
Statistical significance was attained if P < 0.05.
Ethical statement
All participants provided written informed consent and 
the study was approved by the Medical Ethical Review 
Committee of the Arnhem-Nijmegen region.
Results
Patients and controls
At the time of blood collection, the median symptom 
duration of QFS and CFS did not differ significantly 
(P = 0.27), nor did the median age (P = 0.95) and gender 
of all groups (Table  1). All QFS patients and asympto-
matic Q fever seropositive controls had IgG phase I or 
phase II titres ≥ 1:16, but IgG phase I ≤ 1:512, and none 
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of them showed serological signs of an acute or recent 
Q-fever infection, reflected by IgM antibodies in absence 
of IgG antibodies.
PCA and pathway enrichment analysis
A PCA was performed on the top 500 varying genes and 
found no difference between groups (Fig. 1a), except for 
sex [25] (Fig. 1b). Pathway enrichment analysis was per-
formed  on differentially expressed genes, using a cut-
off P value ≤ 10  ×  10−5, yielding no results. Pathway 
enrichment analysis was then repeated, using a cut-off 
P value ≤ 0.01. Although no apparent immunologic acti-
vation or inhibition was seen when comparing various 
groups, some mitochondrial alterations were observed 
(Additional file 1: Table S4A–E).
Genes of interest
Using a cut-off differential expression value > and < 2-fold 
change, together with a cut-off P value ≤ 10 ×  10−5, on 
both up- and down-regulated genes, several appear to 
be of interest (Fig.  2). When comparing CFS to healthy 
controls, those are MT-RNR2 (−  5.2 log 2 fold change; 
P = 3.49  ×  10−11), MT-RNR1 (−  4.4 log 2 fold change; 
P = 2.71  ×  10−9) and AC010970.2 (−  3.8 log 2 fold 
change; P = 1.28 ×  10−5) for the down- regulated genes 
and NEBL (4.8 log 2 fold change; P = 2.79 × 10−5), PDX1 
Table 1 Characteristics of  healthy controls, chronic fatigue syndrome (CFS) patients, Q fever fatigue syndrome (QFS) 
patients, and asymptomatic Q fever seropositive controls
QFS Q fever fatigue syndrome, CFS chronic fatigue syndrome, IQR interquartile range; CIS Checklist Individual Strength, SD standard deviation, SIP-8 Sickness Impact 
Profile-8
a Symptom duration: time onset of symptoms until blood sampling
Characteristics Healthy controls
(n = 10)
CFS
(n = 10)
QFS
(n = 10)
Q fever seropositives
(n = 10)
Male sex, number (%) 5 (50) 5 (50) 5 (50) 5 (50)
Age, years
Median (IQR)
54 (37–61) 48 (41–52) 43 (40–58) 50 (43–57)
Duration of symptoms,  monthsa
Median (IQR)
– 110 (31–253) 78 (62–87) –
CIS subscale fatigue severity score, 
mean ± SD
– 51 ± 5.1 52 ± 4.1 –
SIP‑8 total score, mean ± SD – 1600 ± 735.0 1474 ± 483.7 –
Fig. 1 Principal‑component analysis of top 500 varying genes. Principal component analysis of RNA sequencing data obtained from the top 500 
varying genes in unstimulated, circulating monocytes of healthy controls (n = 10), CFS patients (n = 10), QFS patients (n = 10), and asymptomatic 
Q fever seropositive controls (n = 10), finding no variation between groups (a). The variation that is seen is based on sex (b). Principal Component 
(PC)1 (x‑axis) represents 21% and PC2 (y‑axis) represents 17% of total variation in data. PC principal component, CFS chronic fatigue syndrome, QFS 
Q fever fatigue syndrome, QS (Q fever seropositives), asymptomatic Q fever seropositive controls
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Fig. 2 Differential gene expression in chronic fatigue syndrome (CFS) patients, Q fever fatigue syndrome (QFS) patients, and asymptomatic Q 
fever seropositive controls, compared to healthy controls, and QFS patients compared to CFS patients and Q fever seropositive controls. Heatmaps 
showing differential expression of down‑ and upregulated genes in circulating monocytes with a cut‑off P value ≤ 10 × 10−5. Down‑ and 
upregulated genes in CFS patients (n = 10), QFS patients (n = 10), and asymptomatic Q fever seropositive controls (n = 10), compared to healthy 
controls (n = 10), down‑ and up‑regulated genes in QFS patients (n = 10) compared to CFS patients (n = 10), and down‑ and upregulated genes 
in QFS patients (n = 10) compared to asymptomatic Q fever seropositive controls (n = 10). Heatmaps are based on level of differential expression, 
measured with log 2 fold change and depicted next to each gene, compared to various control groups. CFS chronic fatigue syndrome, QFS Q fever 
fatigue syndrome, QS asymptomatic Q fever seropositive controls
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(3.9 log 2 fold change; P = 1.71  ×  10−5), AC093865.1 
(3.4 log 2 fold change; P = 1.07  ×  10−5), MGAT4D (3.4 
log 2 fold change; P = 5.33  ×  10−5), AC099506.1 (3.1 
log 2 fold change; P = 1.52  ×  10−5), RORB (2.5 log 2 
fold change; P = 2.93 ×  10−5), KIAA0319 (2.4 log 2 fold 
change; P = 4.02  ×  10−6), and BEST3 (2.2 log 2 fold 
change; P = 9.93  ×  10−5) for the up-regulated genes. 
When comparing QFS to healthy controls, those are 
MT-RNR2 (−  4.8 log 2 fold change; P = 2.19  ×  10−9), 
MT-RNR1 (− 4.9 log 2 fold change; P = 4.69 × 10−8), and 
MTRNR2L1 (−  5.9 log 2 fold change; P = 2.88 ×  10−5) 
for the down-regulated genes and AC093865.1 (4.8 
log 2 fold change; P = 6.73  ×  10−8), ALAS2 (4.1 log 
2 fold change; P = 4.64  ×  10−5), SRGAP1 (3.5 log 2 
fold change; P = 8.09  ×  10−7), AC099506.1 (3.5 log 2 
fold change; P = 1.47  ×  10−6), FOXP2 (3.4 log 2 fold 
change; P = 1.51 ×  10−5), SENP3 (3.1 log 2 fold change; 
P = 9.69  ×  10−6), and MUC4 (2.0 log 2 fold change; 
P = 6.16  ×  10−7) for the up-regulated genes. When 
comparing asymptomatic Q fever seropositive con-
trols to healthy controls, those are SNORD66 (− 4.0 log 
2 fold change; P = 8.71 ×  10−7), MT-RNR2 (−  3.7 log 2 
fold change; P = 1.78  ×  10−6), MT-RNR1 (−  3.2 log 2 
fold change; P = 1.12 ×  10−5), SNORD38A (−  3.1 log 2 
fold change; P = 4.51 ×  10−5), MT-TH (−  2.1 log 2 fold 
change; P = 1.92 × 10−5), and SNORD105 (− 2.0 log 2 fold 
change; P = 6.94  ×  10−5) for the down-regulated genes 
and AC093865.1 (4.9 log 2 fold change; P = 2.19 × 10−10), 
AC016597.1 (4.6 log 2 fold change; P = 9.16  ×  10−7), 
FOXP2 (4.2 log 2 fold change; P = 5.30 ×  10−8), SENP3 
(4.1 log 2 fold change; P = 4.1  ×  10−9), SRGAP1 (4.1 
log 2 fold change; P = 6.42  ×  10−9), AC099506.1 (3.8 
log 2 fold change; P = 5.69  ×  10−8), PDX1 (3.8 log 2 
fold change; P = 4.38  ×  10−5), PRTG (3.7 log 2 fold 
change; P = 6.04 × 10−7), PAQR9 (3.7 log 2 fold change; 
P = 9.17  ×  10−5), LINC01140 (3.2 log 2 fold change; 
P = 2.46  ×  10−5), LRRC63 (2.7 log 2 fold change; 
P = 2.34  ×  10−5), ADH1B (2.7 log 2 fold change; 
P = 9.47  ×  10−5), and CTC -455F18.1 (2.0 log 2 fold 
change; P = 9.38  ×  10−5) for the up-regulated genes. 
When comparing QFS to asymptomatic Q fever sero-
positive controls, this is ALAS2 (4.4 log 2 fold change; 
P = 1.81 × 10−5) for the up-regulated genes.
Expression of MT‑RNR1 and MT‑RNR2
Heatmaps comparing various groups were made depict-
ing genes that are differentially expressed, using a cut-off 
P value ≤ 10 ×  10−5 (Fig.  2). If we consider down regu-
lated genes in patients compared to healthy controls, 
two genes, namely MT-RNR1 and MT-RNR2, were con-
sistently less expressed in CFS patients (− 4.4 log 2 fold 
change; P = 2.71  ×  10−9, and −  5.2 log 2 fold change; 
P = 3.49  ×  10−11, respectively), QFS patients (−  4.9 
log 2 fold change; P = 4.69 × 10−8, and − 4.8 log 2 fold 
change; P = 2.19  ×  10−9, respectively), and asympto-
matic Q fever seropositive controls (−  3.2 log 2 fold 
change; P = 1.12  ×  10−5, and −  3.7 log 2 fold change; 
P = 1.78 ×  10−6, respectively) (Figs.  2, 3). Expression of 
MT-RNR1 and MT-RNR2 in individual patients and con-
trols shows that there is a natural variation of expression 
in healthy controls, whilst patient groups all show low 
expression. The median expression is slightly higher in 
asymptomatic Q fever seropositive controls group com-
pared to QFS and CFS (Fig. 3b).
Production of MOTS‑c and humanin
Mitochondrial-derived peptides (MDPs) MOTS-c and 
humanin, respectively encoded by MT-RNR1 and Mt-
RNR2, were measured after stimulation with LPS for 24 h. 
Stimulation of PBMCs with LPS resulted in a decreased 
median production of humanin in QFS patients (371 pg/
mL; IQR 325–384), CFS patients (364 pg/mL; IQR 316–
387), and asymptomatic Q fever seropositive controls 
(354  pg/mL; 292–393), compared to healthy controls 
(395  pg/mL; 372–409) (P = 0.05) (Fig.  4a). No differ-
ence between groups was found for MOTS-c production 
(Fig. 4b).
Discussion
When looking at disease, we found that the transcrip-
tomes of circulating monocytes in QFS patients are not 
grossly different from those of healthy controls, asymp-
tomatic Q fever seropositive controls, and CFS patients. 
Among the limited differences observed, MDP-coding 
genes MT-RNR1 (MOTS-c) and MT-RNR2 (humanin) 
[26, 27] were significantly less expressed (P < 1 × 10−5) in 
all groups of patients as compared to control subjects. To 
further substantiate this finding we stimulated PBMCs 
of these patients with LPS for 24  h and found that this 
resulted in lower production of humanin, but not MOTS-
c, in CFS patients, QFS patients, and asymptomatic Q 
fever seropositive controls, compared to healthy controls.
Humanin and MOTS-c are MDPs and as such may 
act through retrograde signalling, but can also serve in 
an intracellular and endocrine manner [28]. Humanin 
is the first ever described MDP and, studies have shown 
that it mainly acts in an anti-apoptotic and cytoprotec-
tive manner. It has also been implicated in the regulation 
of metabolism and inflammation [29]. Humanin binds to 
the receptor complex CNTFR/WSX-1/gp130, of which 
gp130 is a common subunit of receptors belonging to 
the IL-6 receptor family [30]. Subsequent activation of 
JAK/STAT, AKT and ERK pathways are thought to play 
a role in its cytoprotective effects [26, 30]. Zao et al. have 
shown that LPS stimulation of astrocytes isolated from 
rats, pre-incubated with humanin for 24 h resulted in a 
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decreased production of IL-6, TNFα, and IL-1β [31]. In 
our hands, previous stimulation experiments of PBMCs 
with LPS for 24  h did not result in a difference in IL-6, 
TNFα, or IL-1β production between CFS patients, QFS 
patients, asymptomatic Q fever seropositive controls, and 
healthy controls. However, this does not to mean that 
role of humanin in IL-6, TNFα, and IL-1β production has 
to be discarded. Zao et al. pre-incubated astrocytes with 
extracellular humanin for 24  h before stimulating with 
LPS. This is an experimental setting completely different 
from ours. As we did not find a difference in concentra-
tions of circulating humanin between CFS patients, QFS 
patients, asymptomatic Q fever seropositive controls, 
and healthy controls (data not shown), it is unlikely that 
isolated PBMCs were exposed to different concentrations 
of humanin before LPS stimulation. Furthermore, we 
do not have any insight in the kinetics of humanin pro-
duction by stimulated PBMCs and monocytes. Further 
research on the kinetics and effects of humanin release 
by PBMCs, and especially monocytes, on cytokine pro-
duction is needed.
MOTS-c is the second MDP that was discovered and 
has since been implicated in the regulation of insulin 
resistance and metabolic homeostasis, mainly through 
activation of AMPK [27, 29]. Despite the down-regulated 
transcription for this MDP, we did not find a difference in 
MOTS-c production between groups. In fact, we found 
very low extracellular production (2.47 pg/mL), which is 
Fig. 3 Volcano‑ and boxplots showing differential expression of MT‑RNR1 and MT‑RNR2 in chronic fatigue syndrome (CFS) patients, Q fever 
fatigue syndrome (QFS) patients, and asymptomatic Q fever seropositive controls, compared to healthy controls. Volcanoplots showing differential 
expression of MT‑RNR1 and MT‑RNR2 in circulating monocytes of CFS patients (n = 10), QFS patients (n = 10), and asymptomatic Q fever seropositive 
controls (n = 10), compared to healthy controls (n = 10) (a) and boxplots showing normalised counts of MT‑RNR1 and MT‑RNR2 in circulating 
monocytes of CFS patients (n = 10), QFS patients (n = 10), asymptomatic Q fever seropositive controls (n = 10), and healthy controls (n = 10) (b) CFS 
chronic fatigue syndrome, QFS Q fever fatigue syndrome, QS (Q fever seropositives) asymptomatic Q fever seropositive controls
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the lower limit of the detection range. Although no previ-
ous studies have measured MOTS-c production follow-
ing LPS stimulation, high levels of circulating MOTS-c 
have been found in blood plasma [32, 33], indicating con-
stitutive extracellular production. It could be argued that 
MOTS-c production is regulated through mechanisms 
different to those tested in our experimental setup.
As was previously shown, PBMCs of QFS patients pro-
duce significantly more IL-6 than healthy controls, CFS 
patients, and asymptomatic Q fever seropositive con-
trols, when stimulated with Q fever antigen [8]. This was 
also the case for IL-1β when comparing QFS patients 
with CFS patients and asymptomatic Q fever seropositive 
controls, and TNFα when comparing QFS patients with 
CFS patients and healthy controls. Interestingly, circulat-
ing IL-6 was also significantly increased in QFS patients 
compared to healthy controls, an observation that was 
made before in CFS patients [13, 34]. Looking at the tran-
scriptomes of circulating monocytes in QFS and CFS 
patients, compared to healthy controls, no genes associ-
ated with the IL-6 production pathway seem to be overly 
expressed.
Not much is known on the exact mechanisms through 
which humanin and MOTS-c exert their effects in vari-
ous diseases. Looking at known mechanisms, it could be 
argued that these peptides are important in the patho-
physiology of both CFS and QFS [26, 27, 29]. Their role 
in cell metabolism supports the hypothesis that chronic 
fatigue might result from a hypometabolic state [35–37]. 
It has long been thought that mitochondrial pathol-
ogy underlies chronic fatigue  aetiology, as one of the 
key features of mitochondrial disease is severe fatigue 
[36, 38–41]. Recent studies showed that PBMCs of CFS 
patients show signs of impaired mitochondrial func-
tioning compared to PBMCs of healthy controls when 
stressed [15, 16]. It was also found that CFS patients show 
mitochondrial genetic differences compared to healthy 
controls [17]. It would therefore be of great interest to 
further investigate the role of MT-RNR1 and MT-RNR2 
in these discrepancies and mitochondrial dysfunction in 
chronic fatigue as a whole. Other than its role in regulat-
ing metabolism, humanin also serves as a neuroprotective 
factor that could potentially influence neuroinflamma-
tion by downplaying activation of microglia. This would 
fit with the PET-CT study by Nakatomy et  al. in which 
CFS patients show signs of neuroinflammation [42]. A 
decreased expression of humanin might very well lead to 
the neuroinflammatory processes that were seen in these 
patients. These processes might explain the neurocogni-
tive problems, e.g., memory loss, impaired concentration, 
etc., these patients often concomitantly experience [6]. 
Levels of circulating humanin and MOTS-c have been 
described to decline with age, an interesting observation 
as chronically fatigued patients often describe themselves 
as suddenly having aged significantly [27, 43]. MOTS-c is 
also known to regulate muscle metabolism and has been 
implicated in the regulation of exercise [27]. A deficiency 
of this peptide might therefore be involved in common 
complaints of muscle ache and exercise intolerance in 
CFS and QFS.
It is intriguing that MT-RNR1 and MT-RNR2 were less 
expressed in asymptomatic Q fever seropositive controls, 
albeit to a lesser extent than in QFS and CFS patients. It 
is conceivable that an acute Q fever infection leads to a 
Fig. 4 Production of mitochondrial‑derived peptides (MDP) humanin and MOTS‑c after 24 h stimulation of PBMCs with LPS. LPS‑induced median 
MDP production after 24 h incubation of PBMCs of healthy controls (n = 10), CFS patients (n = 10), QFS patients (n = 10), and asymptomatic Q 
fever seropositive controls (n = 10). a LPS‑induced median humanin production after 24 h incubation of PBMCs, showing a significant difference 
in humanin production between healthy controls (395 pg/mL; 372–409) and CFS patients (364 pg/mL; IQR 316–387), QFS patients (371 pg/mL; 
IQR 325–384), and asymptomatic Q fever seropositive controls (354 pg/mL; 292–393) (P = 0.05). b LPS‑induced median MOTS‑c production after 
24 h incubation of PBMCs, showing no significant difference in MOTS‑c production between healthy controls and CFS patients, QFS patients, and 
asymptomatic Q fever seropositive controls. Data are depicted as median with IQR. QFS Q fever fatigue syndrome, CFS chronic fatigue syndrome, Q 
fever seropositives Q fever seropositive controls, LPS lipopolysaccharide, MDP mitochondrial‑derived peptide, PBMC peripheral blood mononuclear 
cell, IQR interquartile range. **P ≤ 0.01, *P ≤ 0.05
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decreased expression of these genes, Raijmakers, 2018 
(unpublished data), which is then maintained in the long 
term, possibly through epigenetic remodeling [44]. The 
fact that some acute Q fever patients remain fatigued fol-
lowing their infection could suggest that a concomitant, 
perhaps psychological, incentive is needed to induce a 
clinical chronic fatigue syndrome.
In addition to the differential expression of MT-
RNR1 and MT-RNR2, up-regulated genes AC093865.1 
and AC099506.1 are of particular interest as they show 
potential to differentiate chronically fatigued patients as 
a whole from healthy controls. Another gene of interest 
is ALAS2, which is up-regulated in QFS patients com-
pared to both healthy controls and asymptomatic Q fever 
seropositive controls, making it potentially specific for 
QFS. Expression of ALAS2 regulates haem systhesis and 
is upregulated by haem and iron [45]. Loss-of-function 
mutations in this gene are associated with sideroblastic 
anaemias, while gain-of-function mutations are associ-
ated with porphyria [46, 47]. Interestingly, QFS patients 
often exhibit increased levels of ferritin [12]. It would be 
worthwhile to further investigate the role of ALAS2 in 
the pathogenesis of QFS. A particularly crucial question 
would be whether up-regulation of this gene results in 
increased levels of ferritin or vice versa.
Other than the differential expression of MT-RNR1 
and MT-RNR2, no clear alterations were detected in the 
transcriptomes of circulating monocytes when compar-
ing between various groups. This was however a scenario 
we accounted for as previous studies on chronic fatigue 
have only found subtle immunologic differences, which 
are then often contradicted by subsequent studies [13]. 
If there is indeed an immunologic component at play, it 
is likely to a subtle one. As previous stimulation experi-
ments did result in differences in cytokine production 
and patients often experience setbacks following incen-
tives such as infections and excessive exercise, it might 
be worthwhile to investigate the transcriptomes of stimu-
lated, instead of circulating, monocytes.
Conclusion
QFS patients, CFS patients, and, to a lesser extent, 
asymptomatic Q fever seropositive controls showed a 
decreased expression of MDP-coding genes MT-RNR1 
and MT-RNR2, resulting in a decreased production of 
humanin (MT-RNR2), compared to healthy controls. 
Whether these MDP-coding genes play a role in chronic 
fatigue syndromes such as CFS and QFS remains unclear. 
The fact that we find a decreased expression of these 
genes in asymptomatic Q fever seropositive controls as 
well is interesting. It could mean that these findings sim-
ply are not specific for chronic fatigue, or it could tell us 
that acute Q fever is not the only incentive needed to 
induce the clinical syndrome of chronic fatigue. Given 
the functions of MOTS-c and humanin, it is definitely 
worthwhile to further investigate the role of these MDP-
coding genes in chronic fatigue.
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